Dermatology Trials

  • 31/03/2022

    SOLAR: A Phase 2 Randomized Open-label Parallel-group Active Comparator Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymphoma (CTCL) Mycosis Fungoides (MF) Subtype

    View Trial
  • 30/04/2022

    PARCT

    Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IV mycosis fungoides/sezary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT)

    View Trial
  • 30/09/2022

    SPECTA

    SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

    View Trial
  • 01/08/2023

    Investigating the immune response to haematological malignancies with a view to novel therapies

    View Trial
  • 01/12/2019

    RESMAIN

    A multicentre double blind randomised placebo-controlled Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study

    View Trial
  • 30/08/2015

    035 Continuation study

    An open-label treatment-option protocol of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma systemic anaplastic large cell lymphoma or CD30-positive cutaneous T-cell lymphoma

    View Trial
  • 21/07/2030

    PROCLIPI

    Multicenter Observational Prospective Study for the Identification of Prognostic Factors in Patients With Mycosis Fungoides/sezary Syndrome: Proposal for An International Prognostic Index for Cutaneous Lymphoma

    View Trial
  • 31/03/2027

    Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: A randomized phase III trial of the EORTC Melanoma Group

    View Trial
  • 31/05/2021

    EczTend

    Long-term extension trial in subjects with atopic dermatitis who participated in previous tralokinumab trials – ECZTEND

    View Trial
  • 31/03/2021

    Phase 4 Placebo Controlled Study of the Impact of Apremilast on Quality of Life Efficacy and Safety in Subjects with Manifestations of Plaque Psoriasis and Impaired Quality of Life

    View Trial